Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Richard P, Schlenk"'
Autor:
Sabine Kayser, Khaled Sanber, Giovanni Marconi, Agnese Mattei, Marlise R. Luskin, Amar Kelkar, Marco Cerrano, Daniel Tuyet Kristensen, Anne Stidsholt Roug, Chiara Sartor, Fabio Giglio, Marta Riva, Lorenzo Rizzo, Francesco Saraceni, Selene Guerzoni, Federica Lessi, Erika Borlenghi, Mark J. Levis, Richard F. Schlenk, Tania Jain, Cristina Papayannidis
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
We evaluated response to VEN/HMA in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease (EMD). Median age was 65 (range, 19-81) years. Patients had a median of two EMD sites (range, 1-5) and 35 (76%) patients had con
Externí odkaz:
https://doaj.org/article/c5e4bbe9039445ce81f108582a7f9cc3
Autor:
Richard F. Schlenk
Publikováno v:
Haematologica, Vol 109, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/53754e9900e34e60a1755f19b3bf5968
Autor:
Sonia Jaramillo, Michael Scherer, Chelsea Szu-Tu, Sergi Beneyto-Calabuig, Carsten Müller-Tidow, Richard F. Schlenk, Michael Hundemer, Lars Velten, Caroline Pabst
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/a19aac35889a4f3c86484832583752d9
Autor:
Andreas Mock, Maria-Veronica Teleanu, Simon Kreutzfeldt, Christoph E. Heilig, Jennifer Hüllein, Lino Möhrmann, Arne Jahn, Dorothea Hanf, Irina A. Kerle, Hans Martin Singh, Barbara Hutter, Sebastian Uhrig, Martina Fröhlich, Olaf Neumann, Andreas Hartig, Sascha Brückmann, Steffen Hirsch, Kerstin Grund, Nicola Dikow, Daniel B. Lipka, Marcus Renner, Irfan Ahmed Bhatti, Leonidas Apostolidis, Richard F. Schlenk, Christian P. Schaaf, Albrecht Stenzinger, Evelin Schröck, Daniel Hübschmann, Christoph Heining, Peter Horak, Hanno Glimm, Stefan Fröhling
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-15 (2023)
Abstract Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional studies have s
Externí odkaz:
https://doaj.org/article/47ffdc7c0d55467aa0a4083d56bfaa6d
Autor:
Maximilian Schmutz, Manuela Zucknick, Richard F. Schlenk, Daniel Mertens, Axel Benner, Dieter Weichenhan, Oliver Mücke, Konstanze Döhner, Christoph Plass, Lars Bullinger, Rainer Claus
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-16 (2023)
Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from treatment with hypomethyl
Externí odkaz:
https://doaj.org/article/97807982449d429dbc05a64bad75bfbb
Autor:
Sonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, Johannes Krisam, Martin Görner, Mathias Hänel, Christoph Röllig, Maxi Wass, Sebastian Scholl, Mark Ringhoffer, Alexander Reichart, Björn Steffen, Sabine Kayser, Jan-Henrik Mikesch, Kerstin Schaefer-Eckart, Jörg Schubert, Thomas Geer, Sonja Martin, Meinhard Kieser, Tim Sauer, Katharina Kriegsmann, Michael Hundemer, Hubert Serve, Martin Bornhäuser, Carsten Müller-Tidow, Richard F. Schlenk
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-15 (2023)
Abstract Background About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high-dose cytarabine
Externí odkaz:
https://doaj.org/article/429cfaca4e8047249e5f275e8cfc363c
Autor:
Jonas S. Heitmann, Richard F. Schlenk, Daniela Dörfel, Sabine Kayser, Konstanze Döhner, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, Jannik Labrenz, Dominic Edelmann, Melanie Märklin, Wichard Vogel, Wolfgang Bethge, Juliane S. Walz, Ludger Große-Hovest, Martin Steiner, Gundram Jung, Helmut R. Salih
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-9 (2023)
Abstract Background About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135, which is abundantly e
Externí odkaz:
https://doaj.org/article/eda9171042184c4a8c77ebbdbd743b38
Autor:
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Olga Eissymont, Martina Crysandt, Martin Görner, Sabine Kayser, Stefan Krause, Christoph Schliemann, Tobias Gaska, Martin Kaufmann, Jens Chemnitz, Markus Schaich, Alexander Hoellein, Uwe Platzbecker, Meinhard Kieser, Carsten Müller-Tidow, Richard F. Schlenk
Publikováno v:
Haematologica, Vol 109, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/6110ce678a984a25bb7312fd7ac070d0
Autor:
Susanne Jung, Richard F. Schlenk, Christopher Hackenbruch, Sandra S.L. Roldan Pinzon, Michael Bitzer, Martin Pflügler, Juliane S. Walz, Gundram Jung, Jonas S. Heitmann, Helmut R. Salih
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionColorectal cancer (CRC) is the third most common cancer worldwide in men and women. In the metastasized stage, treatment options and prognosis are limited. To address the high medical need of this patient population, we generated a CD276x
Externí odkaz:
https://doaj.org/article/7f1c1453e6734dea9e21b4666171cfeb
Autor:
Anke S. Lonsdorf, Dominic Edelmann, Thomas Albrecht, Alexander Brobeil, Jannik Labrenz, Moritz Johanning, Richard F. Schlenk, Benjamin Goeppert, Alexander H. Enk, Ferdinand Toberer
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Beyond established anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) and its ligand CD155 are promising novel
Externí odkaz:
https://doaj.org/article/72f8575a80c34373914d45e3bb351628